PREMIUM NEWS ARCHIVE
Article from: Cancer Weekly
Article date: November 25, 2008
"This commentary discusses the retrospective study by Weight and colleagues, which evaluated the practice patterns of US physicians using androgen deprivation therapy (either medical castration with luteinizing hormone-releasing hormone [LHRH] agonists or surgical castration by orchiectomy) for the treatment of Medicare patients with prostate cancer during 2001-2005. In 2003, the enactment of the Medicare Modernization Act (MMA), which lowered reimbursement for LHRH analog administration, was introduced," scientists in the United ...
Read full article (with a Free Trial at HighBeam Research)